Literature DB >> 11092502

High-density lipoproteins from human alcoholics exhibit impaired reverse cholesterol transport function.

M N Rao1, Q H Liu, P Marmillot, L B Seeff, D B Strader, M R Lakshman.   

Abstract

We have previously shown that chronic alcohol consumption leads to inhibition of sialylation of apolipoprotein E (apo E) that results in its impaired binding to high-density lipoprotein (HDL) molecule. Because apo E plays a major role in reverse cholesterol transport (RCT), we speculated that ethanol-mediated formation of HDL molecules without apo E may affect the RCT process. Therefore, we have investigated whether the RCT function of HDL is affected in chronic alcoholics with or without liver disease compared with nondrinkers. HDL was isolated from fasting plasma of normal subjects, n = 9 (nondrinkers), chronic alcoholics, n = 8 (ALC), and chronic alcoholics with liver disease, n = 6 (ALD). A portion of HDL sample from each subject was evaluated for its cholesterol efflux capacity from [3H]cholesterol oleate preloaded mouse macrophages. The remaining portion of each HDL sample was labeled with [3H]cholesterol oleate and evaluated for its ability to deliver cholesterol to the liver using HepG2 cells in culture. Cholesterol efflux capacity of HDLs was decreased by 83% (P < .0002) in alcoholics without liver disease and by 84% (P < .0006) in alcoholics with liver disease compared with the HDLs from nondrinkers. The capacities of HDLs to deliver cholesterol to the liver were decreased by 54% (P < .005) in alcoholics without liver disease and by 64% (P < .005) in alcoholics with liver disease compared with the HDLs from nondrinkers. The fact that further complications by liver disease in alcoholic subjects did not significantly exacerbate the extent of impairment in RCT function of HDL suggest that alcohol per se is responsible for its deleterious effects on RCT. Significantly, plasma HDL apo E concentration relative to that of apo A1 (apo E/apo A1 ratio) was also decreased by 31% to 32% (P < .0005) in alcoholics without or with liver disease compared with nondrinkers. It is therefore concluded that chronic alcohol consumption adversely affects the RCT function of HDL by altering its association with apo E due to ethanol-induced desialylation of apo E.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11092502     DOI: 10.1053/meta.2000.17728

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

Review 1.  Effects of ethanol intake on lipoproteins.

Authors:  Eliot A Brinton
Journal:  Curr Atheroscler Rep       Date:  2012-04       Impact factor: 5.113

2.  Long-term ethanol consumption impairs reverse cholesterol transport function of high-density lipoproteins by depleting high-density lipoprotein sphingomyelin both in rats and in humans.

Authors:  Philippe Marmillot; Jennifer Munoz; Sanket Patel; Mamatha Garige; Richard B Rosse; M Raj Lakshman
Journal:  Metabolism       Date:  2007-07       Impact factor: 8.694

3.  Is alcohol beneficial or harmful for cardioprotection?

Authors:  Raj Lakshman; Mamatha Garige; Maokai Gong; Leslie Leckey; Ravi Varatharajalu; Samir Zakhari
Journal:  Genes Nutr       Date:  2010-06       Impact factor: 5.523

4.  Low-ω3 Fatty Acid and Soy Protein Attenuate Alcohol-Induced Fatty Liver and Injury by Regulating the Opposing Lipid Oxidation and Lipogenic Signaling Pathways.

Authors:  Karina Reyes-Gordillo; Ruchi Shah; Ravi Varatharajalu; Mamatha Garige; Leslie C Leckey; M Raj Lakshman
Journal:  Oxid Med Cell Longev       Date:  2016-12-18       Impact factor: 6.543

5.  Effects of water extracts of Graptopetalum paraguayense on blood pressure, fasting glucose, and lipid profiles of subjects with metabolic syndrome.

Authors:  Chi-Hua Yen; Shu-Ju Chen; Jen-Tzu Liu; Yu-Fen Tseng; Ping-Ting Lin
Journal:  Biomed Res Int       Date:  2013-11-25       Impact factor: 3.411

Review 6.  High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives.

Authors:  Maria Pia Adorni; Nicoletta Ronda; Franco Bernini; Francesca Zimetti
Journal:  Cells       Date:  2021-03-05       Impact factor: 7.666

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.